Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, to co-develop a next generation bone allograft solution for use in spine and trauma surgery. Terms of the agreement were not disclosed.
Tony Bihl, CEO of Bioventus, comments, “Orthobiologics will continue to evolve to meet the needs of patients, surgeons and payers and Bioventus is pleased to begin work on the next generation of bone graft solutions with LifeLink. This approach is consistent with our strategy to grow sales of our existing products in the surgical orthobiologics space and expand our offering with new product innovations.”
Jean Davis, President and CEO of LifeLink Foundation, further explains: “The gift of tissue donation is invaluable and offers the opportunity to benefit so many patients in need. Companies like Bioventus are helping to further enhance the immeasurable impact of tissue donations by investing in research and development to bring new solutions to the market and we are excited for our research teams to collaborate together on this development initiative.”
Bioventus is an orthobiologics company, with existing products including offerings for bone healing, bone graft and knee osteoarthritis. LifeLink Foundation is an independent, non-profit community service organisation dedicated to the recovery and transplantation of organs and tissue, headquartered in Tampa, Florida.